We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+10.56%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$1.98B
AUM Growth
+$247M
Cap. Flow
+$143M
Cap. Flow %
7.22%
Top 10 Hldgs %
27.18%
Holding
159
New
18
Increased
48
Reduced
15
Closed
10

Top Buys

Rank Stock Value
1
MDT icon
Medtronic
MDT
+$33.7M
2
UNH icon
UnitedHealth
UNH
+$26.1M
3
AET
Aetna Inc
AET
+$23.7M
4
MRSN
Mersana Therapeutics
MRSN
+$21.1M
5
TMO icon
Thermo Fisher Scientific
TMO
+$18.5M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$27.3M
2
SHPG
Shire pic
SHPG
+$24.2M
3
BMY icon
Bristol-Myers Squibb
BMY
+$21.9M
4
AMGN icon
Amgen
AMGN
+$16.1M
5
PTHN
Patheon N.V.
PTHN
+$10.5M

Sector Composition

Rank Sector Weight
1 Healthcare 79.63%
2 Financials 3.78%
3 Consumer Discretionary 1.13%
4 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EW icon
26
Edwards Lifesciences
EW
$51.6B
$22.5M 1.13%
570,003
+142,503
+33% +$5.2M
AFAM
27
DELISTED
Almost Family Inc
AFAM
$22.3M 1.13%
362,000
+137,000
+61% +$7.5M
GILD icon
28
Gilead Sciences
GILD
$168B
$22.2M 1.12%
313,400
+26,900
+9% +$1.79M
INCY icon
29
Incyte
INCY
$24.4B
$21.8M 1.1%
173,000
+4,000
+2% +$509K
CLVS
30
DELISTED
Clovis Oncology, Inc.
CLVS
$21.7M 1.09%
231,500
+47,000
+25% +$2.88M
MRSN
31
DELISTED
Mersana Therapeutics
MRSN
$21.3M 1.08%
+61,116
New +$21.1M
NBIX icon
32
Neurocrine Biosciences
NBIX
$16.9B
$19.3M 0.97%
419,000
+9,000
+2% +$437K
JAZZ icon
33
Jazz Pharmaceuticals
JAZZ
$16.4B
$19.2M 0.97%
123,700
– –
TMO icon
34
Thermo Fisher Scientific
TMO
$209B
$19.2M 0.97%
+110,000
New +$18.5M
HOLX
35
DELISTED
Hologic
HOLX
$19.1M 0.96%
420,000
+80,000
+24% +$3.53M
DHR icon
36
Danaher
DHR
$137B
$19M 0.96%
253,800
+73,320
+41% +$5.49M
WMGI
37
DELISTED
Wright Medical Group Inc
WMGI
$18.4M 0.93%
670,000
– –
MOH icon
38
Molina Healthcare
MOH
$9.99B
$18.2M 0.92%
+263,500
New +$16.2M
BCR
39
DELISTED
CR Bard Inc.
BCR
$18.2M 0.92%
+57,500
New +$17.1M
EPZM
40
DELISTED
Epizyme, Inc
EPZM
$17.7M 0.9%
1,175,000
+605,000
+106% +$9.15M
AMRN
41
Amarin Corp
AMRN
$302M
$17.1M 0.86%
212,500
-37,560
-15% -$2.34M
LKFT
42
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.73B
$16.9M 0.86%
221,500
+11,500
+5% +$967K
PRTA icon
43
Prothena Corp
PRTA
$444M
$16.8M 0.85%
309,500
– –
VRTX icon
44
Vertex Pharmaceuticals
VRTX
$121B
$16.6M 0.84%
129,000
+38,500
+43% +$4.63M
PBYI icon
45
Puma Biotechnology
PBYI
$397M
$16.3M 0.82%
186,000
+91,500
+97% +$5.12M
WTW icon
46
Willis Towers Watson
WTW
$31.5B
$16M 0.81%
110,000
– –
EXAS
47
DELISTED
Exact Sciences
EXAS
$15.5M 0.78%
437,500
+100,000
+30% +$3.09M
PRTK
48
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$14.5M 0.73%
600,000
+74,500
+14% +$1.65M
BIIB icon
49
Biogen
BIIB
$30.8B
$14.4M 0.73%
53,000
+5,000
+10% +$1.32M
AVXS
50
DELISTED
AveXis, Inc. Common Stock
AVXS
$14.4M 0.73%
175,000
+35,000
+25% +$2.62M
1
2
3 4 5

Similar funds

AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
FDP
Financiere des Professionnels Montreal, Quebec, Canada $1.71B AUM 21.77% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return

Rock Springs Capital Management's Q2 2017 Portfolio in Review

As of Q2 2017, Rock Springs Capital Management held 159 positions worth $1.98B, up 14% from $1.73B the previous quarter. Its ten largest holdings account for 27% of the portfolio.

Rock Springs Capital Management deployed $143M of net new capital in Q2 2017, opening 18 new positions and adding to 48 existing holdings. Its largest new stake was Medtronic: 400,000 shares worth $35.5M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 82% a quarter earlier, followed by Financials and Consumer Discretionary.

On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $21.9M trimmed.

  • Rock Springs Capital Management's largest Q2 2017 buy was Medtronic: 400,000 shares worth $35.5M.
  • Rock Springs Capital Management added most to UnitedHealth in Q2 2017, an estimated $26.1M increase.
  • Rock Springs Capital Management's biggest Q2 2017 reduction was Bristol-Myers Squibb, cutting an estimated $21.9M.
  • Rock Springs Capital Management fully exited Eli Lilly in Q2 2017, selling an estimated $27.3M.
  • Rock Springs Capital Management's ten largest holdings make up 27% of its $1.98B portfolio in Q2 2017.
  • Rock Springs Capital Management opened 18 new positions and closed 10 in Q2 2017.
  • Rock Springs Capital Management's portfolio value rose 14% quarter-over-quarter to $1.98B.

Based on Rock Springs Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.